Clinical trial NCT03040180: Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Official title: Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Randomized Clinical Phase II Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Locally Advanced Rectal Cancer
Electrochemotherapy
Neoadjuvant Therapy
Down Staging
Keywords: Neoplasms
Neoplasms, primary
Cancer
Colorectal cancer
rectal cancer
rectal cancer, locally advanced
Electrochemotherapy
Electroporation
Neoadjuvant therapy
Antineoplastic, antibodies
Bleomycin
Pathologic processes
Neoplastic processes
Lead sponsor: Zealand University Hospital
Sponsor class: OTHER
Collaborators: name: Herlev Hospital
name: Rigshospitalet, Denmark
First posted: 2017-02-02
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of neoadjuvant electrochemotherapy on locally advanced rectal cancer (UICC II-III) in an intended curative clinical setting, using an endoscopic electroporation device (EndoVE).

Detailed description: Electroporation of cancer cells allows for a greater concentration of chemotherapy drugs to enter the tumor cells. The uptake of the chemotherapeutic drug is aided through the application of short electric pulses to the tumor mass (referred to as - Electrochemotherapy or ECT). The pulses make the tumor cells more porous which allows the drug easier access into the cancer cells, whereas other tissues and organs in the body remain relatively poor at absorbing the drug, thereby reducing the potential side effects on healthy tissues. Procedures with electrochemotherapy have previously been applied to human patients in other countries of the EU, the US and Japan.

The drug concentration used is significantly reduced due to the more targeted absorption by the tumor and this significantly reduces side effects normally associated with chemotherapy.

A large number of preclinical and clinical Phase I and I/II studies have demonstrated the efficiency and safety of ECT. These studies have included patients with melanoma, head and neck squamous cell carcinoma, merkel cell carcinomas, basal cell carcinoma and adenocarcinoma nodules.

An endoscopic system (EndoVE ) for delivering the electric pulses to gastrointestinal tumors has recently been developed. The treatment procedure is similar to standard endoscopic colorectal examination (therapeutic colonoscopy) with the added element of an intravenous injection of bleomycin followed by the delivery of electric pulses (each one less than 1msec in duration). The pulses are endoscopically delivered directly to the tumor mass. The entire procedure is minimally invasive and completely ambulatory. A successful treatment will cause the tumor to shrink in size in the weeks following the procedure.

The objective of this study is to investigate the efficacy and safety of this approach in downsizing locally advanced rectal tumors prior to intended curative surgery.

Time frame:

1. All patients will be treated with standard neoadjuvant chemoradiation therapy prior to enrollment in this trial.
2. Alle patients will have PET/MRI scans performed twice to evaluate treatment response (before and after ECT)
3. ECT treatment will be performed 4 weeks prior to surgery outlined by MDT.
4. Alle patients will be followed up for 3 months.

Eligibility criteria: Inclusion Criteria:

1. Patient must be mentally capable of understanding the information given.
2. Patients must give written informed consent.
3. Men or women aged at least 18 years.
4. Histologically verified rectal tumor (adenocarcinoma)
5. Case reviewed by MDT (surgery, radiology, oncology). Case considered curable with neoadjuvant therapy followed by surgical excision (UICC stadium II-III).
6. ASA class I-III (Classification of the American Society of Anesthesiology)

Exclusion Criteria:

1. Coagulation disorders
2. Highly inflamed gastrointestinal tissue which is ulcerated and bleeding
3. Patients with ICD or pacemaker units.
4. Patients with epilepsy.
5. Pregnancy or lactation/breastfeeding.
6. Patients with known Hepatitis B/C or HIV infection.
7. Patients who have undergone treatment with bevacizumab within 4 weeks prior to enrolment in this trial.
8. Patients with concomitant use of phenytoin.
9. Patients with concomitant use of clozapine.
10. Concurrent treatment with an investigational medicinal product.
11. Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study recruitments.
12. Patients with contraindications for PET/MRI scan:
13. Advanced tumor stage, UICC stage IV.
14. Acute pulmonary infection.
15. Medical history of severe pulmonary disease.
16. Previous allergic reactions to bleomycin.
17. Previous cumulative dose of bleomycin exceeding 250.000 IU/m2.
18. Pre-existing renal dysfunction. Creatinine clearance \< 40 ml/min.
19. Platelet count ≤50 mia/l.
20. Prothrombin time ≥ 40 sec
21. Patients registered in the Danish Tissue Register (Vaevsanvendelsesregistret)

Primary outcomes:
measure: Histopathologic tumor regression following electrochemotherapy
timeFrame: 4 weeks
Secondary outcomes:
measure: Treatment safety of electrochemotherapy
timeFrame: 4 months
measure: Treatment safety of surgery following electrochemotherapy
timeFrame: 4 weeks
measure: Tumor regression according to Hybrid PET/MRI following electrochemotherapy
timeFrame: 4 weeks
measure: Tumor Immunologic response following electrochemotherapy
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Herlev
country: Denmark
facility: Department of Oncology
state: Capitol Region
city: Roskilde
country: Denmark
facility: Department of Surgery
Study officials:
affiliation: Department of Surgery, Zealand University Hospital
name: Ismail Gögenur, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of oncology, herlev Hospital
name: Julie Gehl, MD, DMSc
role: PRINCIPAL_INVESTIGATOR
References: